Overview

The purpose of this post-market study is to evaluate the real-world experience of Nevro's Spinal Cord Stimulation (SCS) therapy in patients with chronic, intractable leg pain due to painful diabetic neuropathy (PDN). This is a multicenter, prospective, observational global study, that will partner diabetes management teams with pain physicians to provide an interdisciplinary treatment regimen for PDN patients. Outcomes will be assessed via standardized assessments.

Eligibility

Inclusion Criteria:

To participate in the study, patients must meet all the following inclusion criteria:

1. Have been clinically diagnosed with diabetes, according to the local country diabetes association guidelines, as well as painful diabetic neuropathy (PDN) of the lower limbs refractory to conventional medical management.
2. Average pain intensity (over the last 7 days) of ≥5 out of 10 cm on the Visual Analog Scale (VAS) in the lower limbs at enrollment/baseline.
3. The clinical decision has been made to provide treatment using the Nevro Spinal Cord Stimulation that includes 10 kHz therapy prior to enrollment in the study.
4. Be willing and capable of giving written informed consent.
5. Be willing and able to comply with study-related requirements and procedures and attend all scheduled visits.

Exclusion Criteria:

        To participate in the study, patients must not meet any of the following exclusion
        criteria:
          1. Have a diagnosis of a lower limb mononeuropathy (e.g., causalgia and tibial or
             peroneal neuropathies), have had a lower limb amputation other than toes, or have
             large (≥3 cm) and/or gangrenous ulcers of the lower limbs
          2. Have a medical condition or diagnosis that is inconsistent with Nevro's SCS System
             guidelines in the Physician's Manual for the relevant country, or as per standard
             clinical practice.
          3. Have a medical condition or pain in other areas, not intended to be treated in this
             study, that could interfere with study procedures, accurate pain reporting, and/or
             confound the evaluation of study endpoints, as determined by the Investigator (such as
             primary headache, fibromyalgia, post-herpetic neuralgia, osteoarthritis, peripheral
             vascular disease, or small vessel disease).